March 2013. Volume 9. Number 1

In a whooping cough epidemic, is cocooning a useful strategy?

 
 
 
 
 
 
 
 
 
 
Rating: 4.5 (1 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AAP | Making well-informed clinical decisions based on the current scientific evidence: from the article to the patient

Authors: Ruiz-Canela Cáceres J1, Aizpurua Galdeano P2.
1CS Virgen de África. Sevilla. España.
2ABS 7 La Salut Badalona. Badalona. Barcelona. España.
Correspondence: Juan Ruiz-Canela Cáceres. Email: jruizcanela@gmail.com
Reception date: 21/02/2013
Acceptance date: 22/02/2013
Publication date: 06/03/2013

Abstract

Authors' conclusions: Tdap vaccination of pregnant women from 20 weeks of gestation is the best strategy for preventing morbidity and mortality from pertussis in young infants

Reviewers' commentary: in case of whooping cough epidemic, Tdap vaccination of pregnant women from 20 weeks of gestation can be considered due to the high rates of  mortality and hospitalization among young infants. However, it is necessary that the public health authorities decide the policies to adopt. We think that any experience must be monitored to evaluate mid-and long-term results.

How to cite this article

Ruiz-Canela Cáceres J, Aizpurua Galdeano P. ¿En una epidemia de tos ferina es útil la estrategia de nido? Evid 2013;9:3.

AAP | Making well-informed clinical decisions based on the current scientific evidence: from the article to the patient

Authors: Ruiz-Canela Cáceres J1, Aizpurua Galdeano P2.
1CS Virgen de África. Sevilla. España.
2ABS 7 La Salut Badalona. Badalona. Barcelona. España.
Correspondence: Juan Ruiz-Canela Cáceres. Email: jruizcanela@gmail.com
Reception date: 21/02/2013
Acceptance date: 22/02/2013
Publication date: 06/03/2013

Sorry, there is no English version for this item.

How to cite this article

Ruiz-Canela Cáceres J, Aizpurua Galdeano P. ¿En una epidemia de tos ferina es útil la estrategia de nido? Evid 2013;9:3.

References

  1. Centers for Disease Control and Prevention. Summary Report, June 22-23, 2011. Atlanta, Georgia. Disponible en http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun11.pdf
  2. Health Protection Agency Guidelines for the Public Health Management of Pertussis October 2012. Disponible en http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287142671506
  3. Servicio de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. Comentario Epidemiológico de las Enfermedades de Declaración Obligatoria año 2011. Boletín Epidemiológico Semanal. 2012;20(14):124-39.
  4. Servicio de Vigilancia Epidemiológica. Informe Epidemiológico semanal. Boletín Epidemiológico Electrónico [en línea] [consultado el 09-01-2013]. Disponible en  http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-boletines/fd-boletin-epidemiologico-semanal-red/IS-121226-WEB.pdf
  5. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibióticos para la tos ferina (pertusis) (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
  6. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004 Nov;23:985-9.
  7. Dalhousie University. ClinicalTrials.gov. Pertussis maternal immunization study. Identifier: NCT00553228.
  8. Bechini A, Tiscione E, Boccalini S, Levi M, Bonanni P. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): A review of evidences and recommendations. Vaccine. 2012;30 5179-90.
  9. Zheteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol. 2012;207(1):59.e1-7.
  10. Agencia Española del Medicamento. Boostrix, Suspensión inyectable en jeringa precargada [fecha de publicación febrero 2010] [consultado el 17-01-2013].
  11. Agencia Española del Medicamento. TRIAXIS® suspensión inyectable [fecha de publicación febrero 2010] [consultado el 17-01-2013].
  12. Health Protection Agency. Training Resources Pertussis Pregnancy Program for Health Professionals [fecha de publication octubre 2012] [consultado el 17-01-2013].
06/03/2013

Linked Comment